WO2015015102A3 - Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDF

Info

Publication number
WO2015015102A3
WO2015015102A3 PCT/FR2014/051944 FR2014051944W WO2015015102A3 WO 2015015102 A3 WO2015015102 A3 WO 2015015102A3 FR 2014051944 W FR2014051944 W FR 2014051944W WO 2015015102 A3 WO2015015102 A3 WO 2015015102A3
Authority
WO
WIPO (PCT)
Prior art keywords
agomelatine
contain
pharmaceutical compositions
sulphonic acids
preparing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2014/051944
Other languages
English (en)
Other versions
WO2015015102A2 (fr
Inventor
Hanbin Shan
Yuhui SHEN
Ying Luo
Philippe Letellier
Michael Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Les Laboratoires Servier SAS
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/080337 external-priority patent/WO2015013865A1/fr
Priority claimed from FR1360124A external-priority patent/FR3012142B1/fr
Priority to RU2016106958A priority Critical patent/RU2673080C2/ru
Priority to MX2016001219A priority patent/MX369303B/es
Priority to UAA201601715A priority patent/UA116811C2/uk
Priority to RS20200720A priority patent/RS60440B1/sr
Priority to MEP-2020-125A priority patent/ME03741B/fr
Priority to ES14758162T priority patent/ES2792248T3/es
Priority to EP14758162.3A priority patent/EP3027588B1/fr
Priority to US14/907,670 priority patent/US9573891B2/en
Priority to PL14758162T priority patent/PL3027588T3/pl
Priority to HK16106760.7A priority patent/HK1218745B/zh
Priority to HRP20200927TT priority patent/HRP20200927T1/hr
Priority to SG11201600006RA priority patent/SG11201600006RA/en
Priority to AU2014298304A priority patent/AU2014298304B2/en
Priority to DK14758162.3T priority patent/DK3027588T3/da
Priority to EA201600142A priority patent/EA031237B1/ru
Application filed by Shanghai Institute of Pharmaceutical Industry, Les Laboratoires Servier SAS filed Critical Shanghai Institute of Pharmaceutical Industry
Priority to NZ716151A priority patent/NZ716151A/en
Priority to LTEP14758162.3T priority patent/LT3027588T/lt
Priority to CN201480042633.7A priority patent/CN105473547B/zh
Priority to JP2016530580A priority patent/JP6595990B2/ja
Priority to KR1020167004732A priority patent/KR20160035599A/ko
Priority to SI201431601T priority patent/SI3027588T1/sl
Priority to HK16111309.5A priority patent/HK1223088A1/zh
Priority to CA2919601A priority patent/CA2919601C/fr
Publication of WO2015015102A2 publication Critical patent/WO2015015102A2/fr
Publication of WO2015015102A3 publication Critical patent/WO2015015102A3/fr
Priority to ZA2016/00448A priority patent/ZA201600448B/en
Anticipated expiration legal-status Critical
Priority to CY20201100565T priority patent/CY1123214T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nouveaux complexes d'agomélatine et d'acides sulfoniques de formule (I). Médicaments.
PCT/FR2014/051944 2013-07-29 2014-07-28 Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Ceased WO2015015102A2 (fr)

Priority Applications (25)

Application Number Priority Date Filing Date Title
NZ716151A NZ716151A (en) 2013-07-29 2014-07-28 Novel complexes of agomelatine and sulphonic acids, method for preparing same and the pharmaceutical compositions that contain them
CA2919601A CA2919601C (fr) 2013-07-29 2014-07-28 Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA201600142A EA031237B1 (ru) 2013-07-29 2014-07-28 Новые комплексы агомелатина и сульфокислот, способ их получения и фармацевтические композиции, которые их содержат
UAA201601715A UA116811C2 (uk) 2013-07-29 2014-07-28 Комплекси агомелатину та сульфонових кислот, спосіб їх одержання та фармацевтичні композиції, що їх містять
RS20200720A RS60440B1 (sr) 2013-07-29 2014-07-28 Kompleksi agomelatina i sulfonskih kiselina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
MEP-2020-125A ME03741B (fr) 2013-07-29 2014-07-28 Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES14758162T ES2792248T3 (es) 2013-07-29 2014-07-28 Complejos de agomelatina y ácidos sulfónicos, procedimiento de su preparación y composiciones farmacéuticas que los contienen
EP14758162.3A EP3027588B1 (fr) 2013-07-29 2014-07-28 Complexes d'agomélatine et d'acides sulfoniques, procédé de leur préparation et compositions pharmaceutiques qui les contiennent
US14/907,670 US9573891B2 (en) 2013-07-29 2014-07-28 Complexes of agomelatine and sulphonic acids, a process for their preparation and pharmaceutical compositions containing them
PL14758162T PL3027588T3 (pl) 2013-07-29 2014-07-28 Kompleksy agomelatyny i kwasów sulfonowych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
HK16106760.7A HK1218745B (zh) 2013-07-29 2014-07-28 阿戈美拉汀和磺酸的新复合物、其制备方法和包含其的药物组合物
HRP20200927TT HRP20200927T1 (hr) 2013-07-29 2014-07-28 Kompleksi agomelatina i sulfonskih kiselina, postupak njihove proizvodnje i proizvodnje farmaceutskih pripravaka koji ih sadržavaju
SG11201600006RA SG11201600006RA (en) 2013-07-29 2014-07-28 Novel complexes of agomelatine and sulphonic acids, method for preparing same and the pharmaceutical compositions that contain them
AU2014298304A AU2014298304B2 (en) 2013-07-29 2014-07-28 Novel complexes of agomelatine and sulphonic acids, method for preparing same and the pharmaceutical compositions that contain them
DK14758162.3T DK3027588T3 (da) 2013-07-29 2014-07-28 Komplekser af agomelatin og sulfonsyre, fremgangsmåde til deres fremstilling og lægemiddelsammensætninger som indeholder dem
RU2016106958A RU2673080C2 (ru) 2013-07-29 2014-07-28 Новые комплексы агомелатина и сульфокислот, способ их получения и фармацевтические композиции, которые их содержат
KR1020167004732A KR20160035599A (ko) 2013-07-29 2014-07-28 아고멜라틴 및 설폰산의 신규한 복합체, 이를 제조하기 위한 방법 및 이를 함유하는 약학적 조성물
HK16111309.5A HK1223088A1 (zh) 2013-07-29 2014-07-28 阿戈美拉汀和磺酸的新复合物、其制备方法和包含其的药物组合物
LTEP14758162.3T LT3027588T (lt) 2013-07-29 2014-07-28 Agomelatino ir sulfonrūgščių kompleksai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
CN201480042633.7A CN105473547B (zh) 2013-07-29 2014-07-28 阿戈美拉汀和磺酸的新复合物、其制备方法和包含其的药物组合物
JP2016530580A JP6595990B2 (ja) 2013-07-29 2014-07-28 アゴメラチンとスルホン酸との新規な複合体、これらの製造方法及びこれらを含有する医薬組成物
MX2016001219A MX369303B (es) 2013-07-29 2014-07-28 Nuevos complejos de agomelatina y de acidos sulfonicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
SI201431601T SI3027588T1 (sl) 2013-07-29 2014-07-28 Kompleksi agomelatina in sulfonskih kislin, postopek za pripravo le-teh in farmacevtskih sestavkov, ki jih vsebujejo
ZA2016/00448A ZA201600448B (en) 2013-07-29 2016-01-20 Novel complexes of agomelatine and sulphonic acids, method for preparing same and the pharmaceutical compositions that contain them
CY20201100565T CY1123214T1 (el) 2013-07-29 2020-06-19 Συμπλοκα αγομελατινης και σουλφονικα οξεα, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/080337 2013-07-29
PCT/CN2013/080337 WO2015013865A1 (fr) 2013-07-29 2013-07-29 Complexes d'acides sulfoniques et d'agomélatine et leur préparation
FR1360124A FR3012142B1 (fr) 2013-10-17 2013-10-17 Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1360124 2013-10-17

Publications (2)

Publication Number Publication Date
WO2015015102A2 WO2015015102A2 (fr) 2015-02-05
WO2015015102A3 true WO2015015102A3 (fr) 2015-12-03

Family

ID=51453772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2014/051944 Ceased WO2015015102A2 (fr) 2013-07-29 2014-07-28 Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (26)

Country Link
US (1) US9573891B2 (fr)
EP (1) EP3027588B1 (fr)
JP (1) JP6595990B2 (fr)
CN (1) CN105473547B (fr)
AU (1) AU2014298304B2 (fr)
CA (1) CA2919601C (fr)
CY (1) CY1123214T1 (fr)
DK (1) DK3027588T3 (fr)
EA (1) EA031237B1 (fr)
ES (1) ES2792248T3 (fr)
HK (1) HK1223088A1 (fr)
HR (1) HRP20200927T1 (fr)
HU (1) HUE049928T2 (fr)
LT (1) LT3027588T (fr)
ME (1) ME03741B (fr)
MX (1) MX369303B (fr)
NZ (1) NZ716151A (fr)
PL (1) PL3027588T3 (fr)
PT (1) PT3027588T (fr)
RS (1) RS60440B1 (fr)
RU (1) RU2673080C2 (fr)
SG (1) SG11201600006RA (fr)
SI (1) SI3027588T1 (fr)
UA (1) UA116811C2 (fr)
WO (1) WO2015015102A2 (fr)
ZA (1) ZA201600448B (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2517700A1 (fr) * 2011-04-28 2012-10-31 Zentiva, k.s. Cocristaux pharmaceutiquement acceptables de la N-[2-(7-méthoxy-1-naphthyl)éthyl]acetamide et méthodes de leur préparation
WO2013170738A1 (fr) * 2012-05-14 2013-11-21 上海右手医药科技开发有限公司 Composite à base de radical acide d'agomélatine et procédé de préparation et application associés

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0706044D0 (en) * 2007-03-28 2007-05-09 Syngenta Ltd C0-Crystals
WO2009140466A2 (fr) * 2008-05-14 2009-11-19 Dr. Reddy's Laboratories Ltd. Co-cristaux de linézolide
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
CN102702041B (zh) * 2012-05-14 2013-08-14 上海右手医药科技开发有限公司 阿戈美拉汀苯磺酸类复合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2517700A1 (fr) * 2011-04-28 2012-10-31 Zentiva, k.s. Cocristaux pharmaceutiquement acceptables de la N-[2-(7-méthoxy-1-naphthyl)éthyl]acetamide et méthodes de leur préparation
WO2013170738A1 (fr) * 2012-05-14 2013-11-21 上海右手医药科技开发有限公司 Composite à base de radical acide d'agomélatine et procédé de préparation et application associés

Also Published As

Publication number Publication date
EA201600142A1 (ru) 2016-11-30
JP6595990B2 (ja) 2019-10-23
ES2792248T3 (es) 2020-11-10
UA116811C2 (uk) 2018-05-10
SI3027588T1 (sl) 2020-08-31
RU2016106958A3 (fr) 2018-05-18
NZ716151A (en) 2020-06-26
RS60440B1 (sr) 2020-07-31
DK3027588T3 (da) 2020-07-06
PT3027588T (pt) 2020-06-02
JP2016525566A (ja) 2016-08-25
LT3027588T (lt) 2020-07-10
EA031237B1 (ru) 2018-12-28
US9573891B2 (en) 2017-02-21
WO2015015102A2 (fr) 2015-02-05
RU2673080C2 (ru) 2018-11-22
US20160159735A1 (en) 2016-06-09
EP3027588A2 (fr) 2016-06-08
HUE049928T2 (hu) 2020-11-30
AU2014298304A1 (en) 2016-02-04
CA2919601A1 (fr) 2015-02-05
ME03741B (fr) 2021-04-20
CA2919601C (fr) 2018-02-27
HK1218745A1 (zh) 2017-03-10
PL3027588T3 (pl) 2020-11-02
SG11201600006RA (en) 2016-02-26
CN105473547B (zh) 2019-10-15
HRP20200927T1 (hr) 2020-09-18
MX369303B (es) 2019-11-05
CY1123214T1 (el) 2021-12-31
CN105473547A (zh) 2016-04-06
EP3027588B1 (fr) 2020-04-01
RU2016106958A (ru) 2017-09-04
ZA201600448B (en) 2017-04-26
HK1223088A1 (zh) 2017-07-21
MX2016001219A (es) 2016-05-26
AU2014298304B2 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
WO2015081257A3 (fr) Dérivés d'aminopyridine utilisés comme inhibiteurs de kinases de la famille tam
CA2894892A1 (fr) Derives d'acide boronique et leurs utilisations therapeutiques
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
HK1248069A1 (zh) 去乙酰氧基微管溶素h及其类似物
WO2014144295A8 (fr) Compositions antibiotiques de ceftolozane
WO2015191945A3 (fr) Formes solides de sofosbuvir
WO2014153495A9 (fr) Nouveaux inhibiteurs de stats3
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
HUP1300646A2 (en) Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015092810A3 (fr) Forme amorphe d'idélalisib
EA201691741A1 (ru) Фармацевтическая композиция
IL272806A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
WO2015002755A3 (fr) Composés pour le traitement du paludisme
WO2015095659A3 (fr) Composition de dispersion solide d'indirubine
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2016073493A3 (fr) Composés antifibrinolytiques
WO2015044434A3 (fr) Fluoro-9-méthyl-β-carboline
WO2014159501A3 (fr) Procédés de préparation de tetrahydroisoquinoleines
WO2017004172A8 (fr) Synthèse totale de shishijimicine a et d'analogues de celle-ci
WO2015015102A3 (fr) Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015186139A3 (fr) Nouveaux polymorphes d'oxalate de ténofovir disoproxil et leur procédé de préparation
MX2016005222A (es) Tinturas acidas, proceso para su produccion y su uso.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480042633.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2919601

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2014758162

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14907670

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/001219

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016530580

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014298304

Country of ref document: AU

Date of ref document: 20140728

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167004732

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201601715

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201600142

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2016106958

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14758162

Country of ref document: EP

Kind code of ref document: A2